A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age

Trial Profile

A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 21 Feb 2018 According to an AstraZeneca media release, full results from this trial will be presented at a forthcoming medical meeting.
    • 21 Feb 2018 According to an AstraZeneca media release, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) in the US for the 2018-2019 season. The recommendation follows the presentation of positive results from this trial.
    • 19 Oct 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top